AH
Andrew Hack
OtherModerateManaging Director at Bain Capital Life Sciences
5
Investments
0
Exits
—
AUM
0.0%
Exit Rate
Get contact info, warm intros & fit scores
Sign up to unlock emails, Signal intro paths, and personalized fit analysis for Andrew Hack.
Investment Thesis & Strategy
Andrew Hack, as Managing Director at Bain Capital Life Sciences, invests in various stages of biotech, diagnostics, medical devices, and pharmaceutical companies, seeking to leverage Bain Capital's resources to accelerate growth and innovation in the life sciences sector.
Investment Activity
Deals per year over the last 8 years
1
20100
20110
20120
20131
20141
20150
20162
2017Portfolio Companies
Selected investments from their portfolio of 5 companies
X
Xilio Therapeutics
Biotech · Series A, 2017
N
Nuvalent
Biotech · Series A, 2017
A
Affinivax
Biotech · Series B, 2015
A
Atea Pharmaceuticals
Biotech · Series A, 2014
J
JenaValve Technology
Healthcare · Series C+, 2010
Frequently Asked Questions
Andrew Hack focuses on Seed stage investments.